The DOI matches its Crossref record; 27 of the 27 references it cites were found in a registry or an index.
Efficacy and Safety of a Novel Dual Modulator of Adenosine Triphosphate-Citrate Lyase and Adenosine Monophosphate-Activated Protein Kinase in Patients With Hypercholesterolemia
Open accessAbstract
Objectives The aim of this study was to assess the lipid-altering efficacy and safety of ETC-1002 in subjects with hypercholesterolemia. Background ETC-1002 is a small molecule that modulates pathways of cholesterol, fatty acid, and carbohydrate metabolism and may have therapeutic benefits in treating hypercholesterolemia and other cardiometabolic risk factors. Methods This multicenter, randomized, double-blind, placebo-controlled, parallel-group trial evaluated patients (n = 177) with elevated low-density lipoprotein cholesterol (LDL-C) (130 to 220 mg/dl), who were stratified by baseline triglycerides (not elevated [ Results ETC-1002 40, 80, and 120 mg lowered least-squares mean ± SE LDL-C levels by 17.9 ± 2.2%, 25.0 ± 2.1%, and 26.6 ± 2.2%, respectively, versus a reduction of 2.1 ± 2.2% with placebo (all, p Conclusions ETC-1002 significantly lowered LDL-C levels up to 27% across a broad range of baseline triglycerides and was generally safe and well tolerated. ETC-1002 has a novel mechanism of action and may be useful for reducing LDL-C. (A Study to Assess the Efficacy and Safety of ETC-1002 in Subjects With Elevated Blood Cholesterol and Either Normal or Elevated Triglycerides; NCT01262638).
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“The overall risk of bias was low 7 of 11 trials [7, 9–12, 15, 16], with 4 trials being assessed as having a moderate risk of bias [8, 13, 14, 17].”
From The Clinical Efficacy and Safety of Bempedoic Acid in Patients at Elevated Risk of Cardiovascular Disease: A Meta-Analysis of Randomized Clinical Trials (2024) · cites this paper as [14]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Friedewald, W. T., Levy, R. I., & Fredrickson, D. S. (1972) · Clinical Chemistry · doi:10.1093/clinchem/18.6.499 · Cited by 32,423
Heart Disease and Stroke Statistics—2012 Update: A Report From the American Heart Association
Writing Group Members, Roger, V. L., Go, A. S., Lloyd-Jones, D. M., Benjamin, E. J., Berry, J. D., Borden, W. B., Bravata, D. M., Dai, S., Ford, E. S., et al. (2012) · Circulation · doi:10.1161/cir.0b013e31823ac046 · Cited by 7,333
Grundy, S. M., Cleeman, J. I., Merz, C. N. B., Brewer, H. B., Clark, L. T., Hunninghake, D. B., Pasternak, R. C., Smith, S. C., & Stone, N. J. (2004) · Circulation · doi:10.1161/01.cir.0000133317.49796.0e · Cited by 6,902
Rosuvastatin to Prevent Vascular Events in Men and Women with Elevated C-Reactive Protein
Ridker, P. M., Danielson, E., Fonseca, F. A. H., Genest, J., Gotto, A. M., Kastelein, J. J. P., Koenig, W., Libby, P., Lorenzatti, A. J., MacFadyen, J. G., et al. (2008) · New England Journal of Medicine · doi:10.1056/nejmoa0807646 · Cited by 6,674
Rosuvastatin to Prevent Vascular Events in Men and Women With Elevated C-Reactive Protein
Ridker, P. M., Danielson, E., Fonseca, F. A. H., Genest, J. J., Gotto, A. M., Kastelein, J. J. P., Köenig, W., Libby, P., Lorenzatti, A. J., MacFadyen, J. G., et al. (2009) · Obstetrical & Gynecological Survey · doi:10.1097/01.ogx.0000344393.60303.0a · Cited by 3,641
Heidenreich, P. A., Trogdon, J. G., Khavjou, O. A., Butler, J., Dracup, K., Ezekowitz, M. D., Finkelstein, E. A., Hong, Y., Johnston, S. C., Khera, A., et al. (2011) · Circulation · doi:10.1161/cir.0b013e31820a55f5 · Cited by 3,208
Statins and risk of incident diabetes: A collaborative meta-analysis of randomised statin trials
Sattar, N., Preiss, D., Murray, H. M., Welsh, P., Buckley, B. M., de Craen, A. J., Seshasai, S. R. K., McMurray, J. J., Freeman, D. J., Jukema, J. W., et al. (2010) · The Lancet · doi:10.1016/s0140-6736(09)61965-6 · Cited by 2,436
Preiss, D. (2011) · JAMA · doi:10.1001/jama.2011.860 · Cited by 1,390
Warnick, G. R., & Albers, J. J. (1978) · Journal of Lipid Research · doi:10.1016/s0022-2275(20)41577-9 · Cited by 1,248
Lipoprotein Particle Analysis by Nuclear Magnetic Resonance Spectroscopy
Jeyarajah, E. J., Cromwell, W. C., & Otvos, J. D. (2006) · Clinics in Laboratory Medicine · doi:10.1016/j.cll.2006.07.006 · Cited by 734
Cited by
Sorted by citations
Bempedoic Acid and Cardiovascular Outcomes in Statin-Intolerant Patients
Nissen, S. E., Lincoff, A. M., Brennan, D., Ray, K. K., Mason, D., Kastelein, J. J. P., Thompson, P. D., Libby, P., Cho, L., Plutzky, J., et al. (2023) · New England Journal of Medicine · doi:10.1056/nejmoa2215024 · Cited by 988
Self-citationSafety and Efficacy of Bempedoic Acid to Reduce LDL Cholesterol
Ray, K. K., Bays, H. E., Catapano, A. L., Lalwani, N. D., Bloedon, L. T., Sterling, L. R., Robinson, P. L., & Ballantyne, C. M. (2019) · New England Journal of Medicine · doi:10.1056/nejmoa1803917 · Cited by 807
Self-citationMetabolic reprogramming and epigenetic modifications on the path to cancer
Sun, L., Zhang, H., & Gao, P. (2021) · Protein & Cell · doi:10.1007/s13238-021-00846-7 · Cited by 818
Pinkosky, S. L., Newton, R. S., Day, E. A., Ford, R. J., Lhotak, S., Austin, R. C., Birch, C. M., Smith, B. K., Filippov, S., Groot, P. H. E., et al. (2016) · Nature Communications · doi:10.1038/ncomms13457 · Cited by 498
Self-citationEfficacy and Safety of Bempedoic Acid in Patients With Hypercholesterolemia and Statin Intolerance
Laufs, U., Banach, M., Mancini, G. B. J., Gaudet, D., Bloedon, L. T., Sterling, L. R., Kelly, S., & Stroes, E. S. G. (2019) · Journal of the American Heart Association · doi:10.1161/jaha.118.011662 · Cited by 432
Metabolic reprogramming in liver fibrosis
Horn, P., & Tacke, F. (2024) · Cell Metabolism · doi:10.1016/j.cmet.2024.05.003 · Cited by 432
Ballantyne, C. M., Banach, M., Mancini, G. B. J., Lepor, N. E., Hanselman, J. C., Zhao, X., & Leiter, L. A. (2018) · Atherosclerosis · doi:10.1016/j.atherosclerosis.2018.06.002 · Cited by 422
Self-citationMetabolic control of epigenetics in cancer
Kinnaird, A. S., Zhao, S., Wellen, K. E., & Michelakis, E. D. (2016) · Nature reviews. Cancer · doi:10.1038/nrc.2016.82 · Cited by 429
ATP-citrate lyase controls a glucose-to-acetate metabolic switch
Zhao, S., Torres, A., Henry, R. A., Trefely, S., Wallace, M., Lee, J. V., Carrer, A., Sengupta, A., Campbell, S. L., Kuo, Y.-M., et al. (2016) · Cell Reports · doi:10.1016/j.celrep.2016.09.069 · Cited by 394
Mendelian Randomization Study of ACLY and Cardiovascular Disease
Ference, B. A., Ray, K. K., Catapano, A. L., Ference, T. B., Burgess, S., Neff, D., Oliver‐Williams, C., Wood, A., Butterworth, A. S., Angelantonio, E. D., et al. (2019) · New England Journal of Medicine · doi:10.1056/nejmoa1806747 · Cited by 345
LDL cholesterol: controversies and future therapeutic directions
Ridker, P. M. (2014) · The Lancet · doi:10.1016/s0140-6736(14)61009-6 · Cited by 274
Lipid management in patients with chronic kidney disease
Ferro, C. J., Mark, P. B., Kanbay, M., Sarafidis, P. A., Heine, G. H., Rossignol, P., Massy, Z. A., Mallamaci, F., Valdivielso, J. M., Małyszko, J., et al. (2018) · Nature Reviews Nephrology · doi:10.1038/s41581-018-0072-9 · Cited by 281
ATP-citrate lyase (ACLY) in lipid metabolism and atherosclerosis: An updated review
Feng, X., Zhang, L., Xu, S., & Shen, A.-Z. (2019) · Progress in Lipid Research · doi:10.1016/j.plipres.2019.101006 · Cited by 242
Xiao, C., Dash, S., Morgantini, C., Hegele, R. A., & Lewis, G. F. (2016) · Diabetes · doi:10.2337/db16-0046 · Cited by 212
The dawn of a new era of targeted lipid-lowering therapies
Tokgözoğlu, L., & Libby, P. (2022) · European Heart Journal · doi:10.1093/eurheartj/ehab841 · Cited by 171
Gutierrez, M. J., Rosenberg, N. L., MacDougall, D. E., Hanselman, J. C., Margulies, J. R., Strange, P., Milad, M. A., McBride, S. J., & Newton, R. S. (2014) · Arteriosclerosis Thrombosis and Vascular Biology · doi:10.1161/atvbaha.113.302677 · Cited by 170
Self-citationUse of ETC-1002 to treat hypercholesterolemia in patients with statin intolerance
Thompson, P. D., Rubino, J., Janik, M. J., MacDougall, D. E., McBride, S. J., Margulies, J. R., & Newton, R. S. (2015) · Journal of clinical lipidology · doi:10.1016/j.jacl.2015.03.003 · Cited by 158
Self-citationHyperlipidemia and cardiovascular disease
Tietge, U. J. F. (2014) · Current Opinion in Lipidology · doi:10.1097/mol.0000000000000051 · Cited by 146
Thompson, P. D., MacDougall, D. E., Newton, R. S., Margulies, J. R., Hanselman, J. C., Orloff, D. G., McKenney, J. M., & Ballantyne, C. M. (2016) · Journal of clinical lipidology · doi:10.1016/j.jacl.2015.12.025 · Cited by 142
Self-citationNicholls, S., Lincoff, A. M., Bays, H. E., Cho, L., Grobbee, D. E., Kastelein, J. J., Libby, P., Moriarty, P. M., Plutzky, J., Ray, K. K., et al. (2021) · American Heart Journal · doi:10.1016/j.ahj.2020.10.060 · Cited by 136
Self-citationNational lipid association annual summary of clinical lipidology 2016
Bays, H. E., Jones, P. H., Orringer, C. E., Brown, W. V., & Jacobson, T. A. (2016) · Journal of Clinical Lipidology · doi:10.1016/j.jacl.2015.08.002 · Cited by 128
Self-citationBempedoic Acid (ETC-1002): an Investigational Inhibitor of ATP Citrate Lyase
Bilen, O., & Ballantyne, C. M. (2016) · Current Atherosclerosis Reports · doi:10.1007/s11883-016-0611-4 · Cited by 119
Self-citationBallantyne, C. M., McKenney, J. M., MacDougall, D. E., Margulies, J. R., Robinson, P. L., Hanselman, J. C., & Lalwani, N. D. (2016) · The American Journal of Cardiology · doi:10.1016/j.amjcard.2016.03.043 · Cited by 119
Self-citationTargeting ATP-Citrate Lyase in Hyperlipidemia and Metabolic Disorders
Pinkosky, S. L., Groot, P. H. E., Lalwani, N. D., & Steinberg, G. R. (2017) · Trends in Molecular Medicine · doi:10.1016/j.molmed.2017.09.001 · Cited by 118
Cicero, A. F. G., Fogacci, F., Hernández, A. V., & Banach, M. (2020) · PLoS Medicine · doi:10.1371/journal.pmed.1003121 · Cited by 109
Bempedoic Acid: First Approval
Markham, A. (2020) · Drugs · doi:10.1007/s40265-020-01308-w · Cited by 99
Is AMPK the savior of the failing heart?
Kim, T. T., & Dyck, J. R. B. (2014) · Trends in Endocrinology and Metabolism · doi:10.1016/j.tem.2014.11.001 · Cited by 102
Samsoondar, J. P., Burke, A. C., Sutherland, B. G., Telford, D. E., Sawyez, C. G., Edwards, J. Y., Pinkosky, S. L., Newton, R. S., & Huff, M. W. (2017) · Arteriosclerosis Thrombosis and Vascular Biology · doi:10.1161/atvbaha.116.308963 · Cited by 96
Self-citationATP-citrate lyase: genetics, molecular biology and therapeutic target for dyslipidemia
Burke, A. C., & Huff, M. W. (2017) · Current Opinion in Lipidology · doi:10.1097/mol.0000000000000390 · Cited by 91
Penson, P. E., Bruckert, É., MARAIS, D. P., Reiner, Ž., Pirro, M., Sahebkar, A., Bajraktari, G., Mirrakhimov, E. M., Rizzo, M., Mikhailidis, D. P., et al. (2022) · Journal of Cachexia Sarcopenia and Muscle · doi:10.1002/jcsm.12960 · Cited by 87
National Lipid Association Annual Summary of Clinical Lipidology 2015
Bays, H. E., Jones, P. H., Brown, W. V., & Jacobson, T. A. (2014) · Journal of clinical lipidology · doi:10.1016/j.jacl.2014.10.002 · Cited by 82
Self-citationBanach, M., Penson, P. E., Farnier, M., Fras, Z., Latkovskis, G., Laufs, U., Paneni, F., Parini, P., Pirro, M., Reiner, Ž., et al. (2023) · Progress in Cardiovascular Diseases · doi:10.1016/j.pcad.2023.03.001 · Cited by 77
New Therapeutic Approaches to the Treatment of Dyslipidemia
Rader, D. J. (2016) · Cell Metabolism · doi:10.1016/j.cmet.2016.01.005 · Cited by 75
Current and future trends in the lipid lowering therapy
Okopień, B., Bułdak, Ł., & Bołdys, A. (2016) · Pharmacological Reports · doi:10.1016/j.pharep.2016.03.016 · Cited by 69
Bempedoic acid: effects on lipoprotein metabolism and atherosclerosis
Burke, A. C., Telford, D. E., & Huff, M. W. (2018) · Current Opinion in Lipidology · doi:10.1097/mol.0000000000000565 · Cited by 67
Gu, C., Li, T. X., Jiang, S., Yang, Z. P., Lv, J., Yi, W., Yang, Y., & Fang, M. (2018) · Ageing Research Reviews · doi:10.1016/j.arr.2018.08.002 · Cited by 66
Nicholls, S. J., Nissen, S. E., Prati, F., Windecker, S., Kataoka, Y., Puri, R., Hucko, T., Kassahun, H., Liao, J., Somaratne, R. M., et al. (2021) · Cardiovascular Diagnosis and Therapy · doi:10.21037/cdt-20-684 · Cited by 65
Minno, A. D., Lupoli, R., Calcaterra, I. L., Poggio, P., Forte, F., Spadarella, G., Ambrosino, P., Iannuzzo, G., & Minno, M. N. D. D. (2020) · Journal of the American Heart Association · doi:10.1161/jaha.119.016262 · Cited by 68
Hegele, R. A., Gidding, S. S., Ginsberg, H. N., McPherson, R., Raal, F. J., Rader, D. J., Robinson, J. G., & Welty, F. K. (2015) · Arteriosclerosis, Thrombosis, and Vascular Biology · doi:10.1161/atvbaha.115.306442 · Cited by 63
Wang, X., Zhang, Y., Tan, H., Wang, P., Zha, X., Chong, W., Zhou, L., & Fang, F. (2020) · Cardiovascular Diabetology · doi:10.1186/s12933-020-01101-9 · Cited by 61
New Era of Lipid-Lowering Drugs
Barter, P. J., & Rye, K. (2016) · Pharmacological Reviews · doi:10.1124/pr.115.012203 · Cited by 59
Lipids, blood pressure and kidney update 2015
Banach, M., Aronow, W. S., Șerban, M.-C., Rysz, J., Voroneanu, L. E., & Covic, A. C. (2015) · Lipids in Health and Disease · doi:10.1186/s12944-015-0169-0 · Cited by 57
Toth, P. P., Bray, S., Villa, G., Palagashvili, T., Sattar, N., Stroes, E. S. G., & Worth, G. M. (2022) · Journal of the American Heart Association · doi:10.1161/jaha.122.025551 · Cited by 56
Ruscica, M., Banach, M., Sahebkar, A., Corsini, A., & Sirtori, C. R. (2019) · Expert Opinion on Pharmacotherapy · doi:10.1080/14656566.2019.1583209 · Cited by 56
Saeed, A., & Ballantyne, C. M. (2018) · Cardiology Clinics · doi:10.1016/j.ccl.2017.12.007 · Cited by 51
Self-citationNew Trends in Dyslipidemia Treatment
Jang, A. Y., Lim, S., Jo, S.-H., Han, S. H., & Koh, K. K. (2020) · Circulation Journal · doi:10.1253/circj.cj-20-1037 · Cited by 62
Contemporary Management of Dyslipidemia
Ferraro, R., Leucker, T. M., Martin, S. S., Banach, M., Jones, S. R., & Toth, P. P. (2022) · Drugs · doi:10.1007/s40265-022-01691-6 · Cited by 59
Evaluating bempedoic acid for the treatment of hyperlipidaemia
Penson, P. E., McGowan, M. P., & Banach, M. (2017) · Expert Opinion on Investigational Drugs · doi:10.1080/13543784.2017.1280458 · Cited by 52
Adipose-Derived Mesenchymal Stem Cells Ameliorate Lipid Metabolic Disturbance in Mice
Liu, G.-Y., Liu, J., Wang, Y., Liu, Y., Shao, Y., Han, Y., Qin, Y.-R., Xiao, F., Li, P., Zhao, L., et al. (2016) · Stem Cells Translational Medicine · doi:10.5966/sctm.2015-0239 · Cited by 52
Adenosine triphosphate citrate lyase: Emerging target in the treatment of dyslipidemia
Lemus, H. N., & Mendivil, C. O. (2015) · Journal of clinical lipidology · doi:10.1016/j.jacl.2015.01.002 · Cited by 49
Lipids, Lipoproteins, and Cardiovascular Disease: Clinical Pharmacology Now and in the Future
Chait, A., & Eckel, R. H. (2016) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2015-3940 · Cited by 48
ETC-1002: A future option for lipid disorders?
Nikolić, D., Mikhailidis, D. P., Davidson, M. H., et al. (2014) · Atherosclerosis · doi:10.1016/j.atherosclerosis.2014.10.099 · Cited by 47
Self-citationPharmacotherapies for lipid modification: beyond the statins
Gotto, A. M., & Moon, J. E. (2013) · Nature Reviews Cardiology · doi:10.1038/nrcardio.2013.117 · Cited by 45
Filippov, S. I., Pinkosky, S. L., & Newton, R. S. (2014) · Current Opinion in Lipidology · doi:10.1097/mol.0000000000000091 · Cited by 44
Self-citationBurke, A. C., Telford, D. E., Sutherland, B. G., Edwards, J. Y., Sawyez, C. G., Barrett, P. H. R., Newton, R. S., Pickering, J. G., & Huff, M. W. (2018) · Arteriosclerosis Thrombosis and Vascular Biology · doi:10.1161/atvbaha.117.310676 · Cited by 46
Self-citationLipid lowering drugs and inflammatory changes: an impact on cardiovascular outcomes?
Ruscica, M., Ferri, N., Macchi, C., Corsini, A., & Sirtori, C. R. (2018) · Annals of Medicine · doi:10.1080/07853890.2018.1498118 · Cited by 43
ATP‐citrate lyase is an epigenetic regulator to promote obesity‐related kidney injury
Chen, Y., Deb, D. K., Fu, X., Yi, B., Liang, Y., Du, J., He, L., & Li, Y. C. (2019) · The FASEB Journal · doi:10.1096/fj.201900213r · Cited by 43
Low-Density Lipoprotein Cholesterol-Lowering Drugs: A Narrative Review
Ferri, N., Ruscica, M., Fazio, S., & Corsini, A. (2024) · Journal of Clinical Medicine · doi:10.3390/jcm13040943 · Cited by 44
An update on pharmacotherapies in diabetic dyslipidemia
Gupta, M., Tummala, R., Ghosh, R. K., Blumenthal, C., Philip, K., Bandyopadhyay, D., Ventura, H. O., & DEEDWANIA, P. C. (2019) · Progress in Cardiovascular Diseases · doi:10.1016/j.pcad.2019.07.006 · Cited by 43
Dai, L., Zuo, Y., You, Q., Zeng, H., & Cao, S. (2020) · European Journal of Preventive Cardiology · doi:10.1177/2047487320930585 · Cited by 42
Bempedoic Acid (ETC-1002): ATP Citrate Lyase Inhibitor
Zagelbaum, N. K., Yandrapalli, S., Nabors, C. C., & Frishman, W. H. (2018) · Cardiology in Review · doi:10.1097/crd.0000000000000218 · Cited by 37
Bempedoic acid for the treatment of dyslipidemia
Marrs, J. C., & Anderson, S. L. (2020) · Drugs in Context · doi:10.7573/dic.2020-6-5 · Cited by 36
A Review of the Efficacy and Tolerability of Bempedoic Acid in the Treatment of Hypercholesterolemia
Niman, S., Rana, K., Reid, J., Sheikh‐Ali, M., Lewis, T., Choksi, R. R., & Goldfaden, R. F. (2020) · American Journal of Cardiovascular Drugs · doi:10.1007/s40256-020-00399-w · Cited by 36
Jadhav, S. B., Crass, R. L., Chapel, S. H., Kerschnitzki, M., Sasiela, W. J., Emery, M. G., Amore, B. M., Barrett, P. H. R., Watts, G. F., & Catapano, A. L. (2021) · European Heart Journal - Cardiovascular Pharmacotherapy · doi:10.1093/ehjcvp/pvab064 · Cited by 36
Recent advances in the pharmacological management of hypercholesterolaemia
Ajufo, E., & Rader, D. J. (2016) · The Lancet Diabetes & Endocrinology · doi:10.1016/s2213-8587(16)00074-7 · Cited by 36
Dyslipidemias in clinical practice
Cabezas, M. C., Burggraaf, B., & Klop, B. (2018) · Clinica Chimica Acta · doi:10.1016/j.cca.2018.09.010 · Cited by 36
Adenosine Triphosphate Citrate Lyase and Fatty Acid Synthesis Inhibition
Lau, F. D., & Giugliano, R. P. (2023) · JAMA Cardiology · doi:10.1001/jamacardio.2023.2402 · Cited by 38
Yenilmez, B., Kelly, M., Zhang, G., Wetoska, N., Ilkayeva, O., Min, K., Rowland, L. A., DiMarzio, C., He, W., Raymond, N., et al. (2022) · Journal of Biological Chemistry · doi:10.1016/j.jbc.2022.102401 · Cited by 36
Brandts, J., & Ray, K. K. (2020) · Expert Opinion on Investigational Drugs · doi:10.1080/13543784.2020.1778668 · Cited by 33
Bandyopadhyay, D., Ashish, K., Hajra, A., Qureshi, A., & Ghosh, R. K. (2018) · Journal of Lipids · doi:10.1155/2018/3179201 · Cited by 32
Wang, X., Luo, S., Gan, X., He, C., & Huang, R. (2019) · Kardiologia Polska · doi:10.5603/kp.a2019.0013 · Cited by 28
New and emerging lipid-modifying drugs to lower LDL cholesterol
Kosmas, C. E., Pantou, D., Sourlas, A., Papakonstantinou, E. J., Uceta, R. E., & Guzman, E. (2021) · Drugs in Context · doi:10.7573/dic.2021-8-3 · Cited by 32
Fernandez-Fuente, G., Rigby, M. J., & Puglielli, L. (2022) · Molecular Metabolism · doi:10.1016/j.molmet.2022.101653 · Cited by 30
New Therapeutic Approaches for Familial Hypercholesterolemia
Ajufo, E., & Rader, D. J. (2018) · Annual Review of Medicine · doi:10.1146/annurev-med-051215-030943 · Cited by 26
Bempedoic Acid: A Promising Novel Agent for LDL-C Lowering
Agarwala, A., & Goldberg, A. C. (2020) · Future Cardiology · doi:10.2217/fca-2020-0016 · Cited by 24
Bempedoic Acid for Heterozygous Familial Hypercholesterolemia: From Bench to Bedside
Agarwala, A., Quispe, R., Goldberg, A. C., & Michos, E. D. (2021) · Drug Design Development and Therapy · doi:10.2147/dddt.s251865 · Cited by 23
New and Emerging LDL Cholesterol–Lowering Drugs
Kosmas, C. E., & Frishman, W. H. (2014) · American Journal of Therapeutics · doi:10.1097/mjt.0000000000000063 · Cited by 23
Sayed, A., Shazly, O., Slipczuk, L., Krittanawong, C., Baloch, F., & Virani, S. S. (2024) · Cardiovascular Drugs and Therapy · doi:10.1007/s10557-023-07474-9 · Cited by 19
Zhao, X., Ma, X.-B., Luo, X., Shi, Z., Deng, Z., Jin, Y., Xiao, Z., Tan, L., Liu, P., Jiang, S., et al. (2020) · BMC Pharmacology and Toxicology · doi:10.1186/s40360-020-00463-w · Cited by 19
Influence of lipid-lowering drugs on inflammation: what is yet to be done?
Ugovšek, S., Zupan, J., Likozar, A. R., & Šebeštjen, M. (2021) · Archives of Medical Science · doi:10.5114/aoms/133936 · Cited by 19
Jia, X., & Virani, S. S. (2019) · Journal of the American Heart Association · doi:10.1161/jaha.119.012352 · Cited by 18
Mutschlechner, D., Tscharre, M., Huber, K., & Gremmel, T. (2023) · European Heart Journal - Cardiovascular Pharmacotherapy · doi:10.1093/ehjcvp/pvad052 · Cited by 17
Colivicchi, F., Fusco, S. A. D., Scicchitano, P., Caldarola, P., Murrone, A., Valente, S., Urbinati, S., Roncon, L., Amodeo, V., Aspromonte, N., et al. (2020) · Journal of Cardiovascular Medicine · doi:10.2459/jcm.0000000000001108 · Cited by 18
Morse, N. (2015) · Lipid Technology · doi:10.1002/lite.201500061 · Cited by 17
Novel treatment options for the management of heterozygous familial hypercholesterolemia
Polychronopoulos, G., & Τζιόμαλος, Κ. (2017) · Expert Review of Clinical Pharmacology · doi:10.1080/17512433.2017.1378096 · Cited by 16
LDL-Cholesterol-Lowering Therapy
Pirillo, A., Norata, G. D., & Catapano, A. L. (2020) · Handbook of experimental pharmacology · doi:10.1007/164_2020_361 · Cited by 17
Bempedoic Acid: Lipid Lowering for Cardiovascular Disease Prevention
Albosta, M. S., Grant, J. K., & Michos, E. D. (2023) · Heart International · doi:10.17925/hi.2023.17.2.1 · Cited by 16
Cardio-Onco-Metabolism – Metabolic vulnerabilities in cancer and the heart
Karlstaedt, A., & Taegtmeyer, H. (2022) · Journal of Molecular and Cellular Cardiology · doi:10.1016/j.yjmcc.2022.06.008 · Cited by 15
Bempedoic Acid in the Treatment of Patients with Dyslipidemias and Statin Intolerance
Susekov, A. V., Король, Л. А., & Watts, G. F. (2021) · Cardiovascular Drugs and Therapy · doi:10.1007/s10557-020-07139-x · Cited by 13
Ácido bempedoico. Mecanismo de acción y propiedades farmacocinéticas y farmacodinámicas
Masana, L., & Plana, N. (2021) · Clínica e Investigación en Arteriosclerosis · doi:10.1016/j.arteri.2021.02.012 · Cited by 15
Comprehensive review of statin-intolerance and the practical application of Bempedoic Acid
Yarrarapu, S. N. S., Goyal, A., Venkata, V. S., Panchal, V. S., Sivasubramanian, B. P., Du, D. T., Jakulla, R. S., Pamulapati, H., Afaq, M. A., Owens, S., et al. (2024) · Journal of Cardiology · doi:10.1016/j.jjcc.2024.03.006 · Cited by 14
Future Lipid-Altering Therapeutic Options Targeting Residual Cardiovascular Risk
Farnier, M. (2016) · Current Cardiology Reports · doi:10.1007/s11886-016-0743-8 · Cited by 14
Emerging therapeutic targets for NASH: key innovations at the preclinical level
Horn, P., & Newsome, P. N. (2020) · Expert Opinion on Therapeutic Targets · doi:10.1080/14728222.2020.1728742 · Cited by 12
Achieving More Optimal Lipid Control with Non-Statin Lipid Lowering Therapy
Nicholls, S. J., & Nelson, A. J. (2025) · Current Atherosclerosis Reports · doi:10.1007/s11883-025-01280-4 · Cited by 12
Agha, A. M., Jones, P. H., Ballantyne, C. M., Virani, S. S., & Nambi, V. (2021) · Journal of clinical lipidology · doi:10.1016/j.jacl.2021.07.002 · Cited by 11
Self-citationMeta-analysis of the Safety and Efficacy of Bempedoic Acid
Khan, M. U., Khan, M. Z., Munir, M. B., Balla, S., & Khan, S. U. (2020) · The American Journal of Cardiology · doi:10.1016/j.amjcard.2020.06.028 · Cited by 11
Novel therapeutic targets and agents for pediatric dyslipidemia
Sunil, B., Foster, C., Wilson, D. P., & Ashraf, A. P. (2021) · Therapeutic Advances in Endocrinology and Metabolism · doi:10.1177/20420188211058323 · Cited by 13
AMPK, a key molecule regulating aging-related myocardial ischemia-reperfusion injury
Yin, X., Guo, Z., & Song, C. (2024) · Molecular Biology Reports · doi:10.1007/s11033-023-09050-8 · Cited by 10
Maghsoodi, N., & Wierzbicki, A. S. (2016) · Current Opinion in Cardiology · doi:10.1097/hco.0000000000000282 · Cited by 10
Tomlinson, B., Chan, P., Zhang, Y., & Lam, C. W. K. (2020) · Expert Opinion on Pharmacotherapy · doi:10.1080/14656566.2020.1801638 · Cited by 11
Metadata
- Authors
- Ballantyne, C. M., Davidson, M. H., MacDougall, D. E., Bays, H. E., DiCarlo, L. A., Rosenberg, N. L., Margulies, J., & Newton, R. S.
- Affiliations
- Houston Methodist (US)
- University of Chicago (US)
- Esperion Therapeutics (United States) (US)
- Louisville Metabolic and Atherosclerosis Research Center (US)
- Corresponding author
- Ballantyne, Christie M.
- Venue
- Journal of the American College of Cardiology
- Publisher
- Elsevier BV
- Published
- 2013-09
- Volume
- 62
- Issue
- 13
- Pages
- 1154-1162
- ISSN
- 0735-1097 (ISSN-L)
- OpenAlex
- W201469966
- Semantic Scholar
- 65747388e68ae65eab0dfc122080ea1ceeab19d5
- Cited by
- 175
- References
- 27
- Citations by year
- 2026: 6 · 2025: 4 · 2024: 15 · 2023: 17 · 2022: 14 · 2021: 18 · 2020: 26 · 2019: 14 · 2018: 13 · 2017: 7 · 2016: 19 · 2015: 10 · 2014: 10 · 2013: 2
- FWCI
- 13.48
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Licence
- Locations
- Journal of the American College of Cardiology (publishedVersion)
- PubMed (publishedVersion)
- Funders
- American Heart Association
- Amgen
- Bristol-Myers Squibb
- AstraZeneca
- GlaxoSmithKline
- Sanofi
- Amarin Corporation
- Esperion Therapeutics
- National Institutes of Health
- U.S. Food and Drug Administration
- Genentech
- Topics
- Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Lipoproteins and Cardiovascular Health
- Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Lipid metabolism and disorders
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Biochemistry › Cholesterol and Lipid Metabolism
- Keywords
- hypercholesterolemia, LDL cholesterol lowering, ATP citrate lyase, AMPK, lipid-lowering therapy, non-HDL cholesterol, apolipoprotein B, LDL particle number, triglycerides, cardiometabolic risk factors, drug safety and tolerability, dose-response relationship, statin-resistant hypercholesterolemia
- MeSH terms
- Aged, Hypolipidemic Agents, ATP Citrate (pro-S)-Lyase, Dicarboxylic Acids, Double-Blind Method, Fatty Acids, Female, Humans, Hypercholesterolemia, Male, Middle Aged, Risk Factors, AMP-Activated Protein Kinases
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
